Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$4.6 million.

  • Zevra Therapeutics' Cash from Investing Activities rose 8540.54% to -$4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 30358.72%. This contributed to the annual value of -$22.2 million for FY2024, which is 2743.53% down from last year.
  • Latest data reveals that Zevra Therapeutics reported Cash from Investing Activities of -$4.6 million as of Q3 2025, which was up 8540.54% from $11.9 million recorded in Q2 2025.
  • Zevra Therapeutics' Cash from Investing Activities' 5-year high stood at $34.0 million during Q2 2023, with a 5-year trough of -$44.5 million in Q3 2023.
  • Over the past 5 years, Zevra Therapeutics' median Cash from Investing Activities value was -$105000.0 (recorded in 2021), while the average stood at -$4.1 million.
  • Per our database at Business Quant, Zevra Therapeutics' Cash from Investing Activities plummeted by 5928076.92% in 2021 and then surged by 1690158.73% in 2023.
  • Zevra Therapeutics' Cash from Investing Activities (Quarter) stood at -$15.4 million in 2021, then skyrocketed by 99.59% to -$63000.0 in 2022, then surged by 16901.59% to $10.6 million in 2023, then plummeted by 151.69% to -$5.5 million in 2024, then increased by 16.36% to -$4.6 million in 2025.
  • Its Cash from Investing Activities was -$4.6 million in Q3 2025, compared to $11.9 million in Q2 2025 and $10.5 million in Q1 2025.